InDex Pharmaceuticals Holding0,796 SEK +1,27 %
HC Andersen Capital saa maksun yhtiöltä InDex Pharmaceuticals Holding DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.Lue lisää